Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion宣佈REC-1245的Phase 1/2臨床研究中首例患者接受劑量，這是一種潛在的首創性Rbm39降解劑，用於生物標記豐富的實體腫瘤和淋巴瘤